Heterocyclic GLP-1 agonists
This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
1. A compound which is:
or a pharmaceutically acceptable salt thereof.
2. A compound which is:
3. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
4. A compound which is:
or a pharmaceutically acceptable salt thereof.
5. A compound which is:
6. A pharmaceutical composition comprising the compound of claim 4 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
7. A compound which is:
or a pharmaceutically acceptable salt thereof.
8. A compound which is:
9. A pharmaceutical composition comprising the compound of claim 7 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
10. A compound which is:
or a pharmaceutically acceptable salt thereof.
11. A compound which is:
12. A pharmaceutical composition comprising the compound of claim 10 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
13. A compound which is:
or a pharmaceutically acceptable salt thereof.
14. A compound which is:
15. A pharmaceutical composition comprising the compound of claim 13 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.